Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Calvin J Cohen

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
AIDS (London, England)|December 31, 2008
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trialCalvin J Cohen, Daniel S Berger, Gary Blick, et al.
AIDS (London, England)|December 6, 2012
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trialsCalvin J Cohen, Jean-Michel Molina, Isabel Cassetti, et al.
Archives of Internal Medicine|April 23, 2002
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelinesSue J Goldie, Jonathan E Kaplan, Elena Losina, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 21, 2012
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE TrialsCalvin J Cohen, Jean-Michel Molina, Pedro Cahn, et al.
AIDS (London, England)|December 20, 2015
Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b studyJan van Lunzen, Andrea Antinori, Calvin J Cohen, et al.
The Journal of Infectious Diseases|March 5, 2005
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimenJacob P Lalezari, Nicholaos C Bellos, Kunthavi Sathasivam, et al.
AIDS (London, England)|April 7, 2007
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis, Jeffrey P Nadler, Daniel S Berger, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
AIDS (London, England)|December 31, 2008
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trialCalvin J Cohen, Daniel S Berger, Gary Blick, et al.
AIDS (London, England)|December 6, 2012
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trialsCalvin J Cohen, Jean-Michel Molina, Isabel Cassetti, et al.
Archives of Internal Medicine|April 23, 2002
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelinesSue J Goldie, Jonathan E Kaplan, Elena Losina, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 21, 2012
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE TrialsCalvin J Cohen, Jean-Michel Molina, Pedro Cahn, et al.
AIDS (London, England)|December 20, 2015
Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b studyJan van Lunzen, Andrea Antinori, Calvin J Cohen, et al.
The Journal of Infectious Diseases|March 5, 2005
T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimenJacob P Lalezari, Nicholaos C Bellos, Kunthavi Sathasivam, et al.
AIDS (London, England)|April 7, 2007
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis, Jeffrey P Nadler, Daniel S Berger, et al.
Pageof 3